Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years

Menopause

Volumn 22, Issue 7, 2015, Pages 694-701

  Gartoulla, Pragya ^a   Worsley, Roisin ^a   Bell, Robin J ^a   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Menopause; Midlife; Vasomotor

Indexed keywords

BIOSIMILAR AGENT; CONTRACEPTIVE AGENT; ESTROGEN; PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; BODY MASS; CLIMACTERIUM; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HIGH SCHOOL; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; SMOKING; VASOMOTOR SYMPTOM; AGE; ESTROGEN THERAPY; HOT FLASHES; MENOPAUSE; ODDS RATIO; PHYSIOLOGY; PREVALENCE; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; RISK FACTOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; STATISTICS AND NUMERICAL DATA; SYMPTOM ASSESSMENT; UTILIZATION;

ADULT; AGE FACTORS; AGED; AUSTRALIA; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; ODDS RATIO; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SMOKING; SURVEYS AND QUESTIONNAIRES; SYMPTOM ASSESSMENT;

EID: 84937045136     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000383     Document Type: Article

References (45)

1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159-1168.
2. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272.
3. Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110(pt 1):230-240.
4. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI [Research Support, Non-US Government Review]. Climacteric 2012;15:267-274.
5. Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med 2005;1:291-300.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
8. Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005;14:837-842.
9. Travers C, O'Neill SM, Khoo SK, King R. Hormones down under: hormone therapy use after the Women's Health Initiative. Aust N Z J Obstetr Gynaecol 2006;46:330-335.
10. Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol 2014;124:727-733.
11. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-3853.
12. Davis SR, Davison SL, Donath S, Bell R. Relationships between circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-96.
13. Jane FM, Davis SR. A practitioner's toolkit for managing the menopause. Climacteric 2014;17:564-579.
14. Bell RJ, Lijovic M, Fradkin P, Davis SR. A pragmatic approach to the classification of menopausal status for community-based research. Menopause 2008;15:978-983.
15. Hilditch JR, Lewis J, Peter A, et al. A Menopause-Specific Quality of Life Questionnaire: development and psychometric properties. Maturitas 2008;61:107-121.
16. Mishra GD, Dobson AJ. Using longitudinal profiles to characterize women's symptoms through midlife: results from a large prospective study [Research Support, Non-US Government]. Menopause 2012;19:549-555.
17. Australian Bureau of Statistics. Australian Demographic Statistics, Dec 2011. Canberra, Australia: Australian Bureau of Statistics; 2011.
18. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas 2007;58:348-358.
19. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society [Practice Guideline Research Support, Non-US Government]. Menopause 2012;19:257-271.
20. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-s66.
21. de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316-337.
22. Geukes M, van Aalst MP, Nauta MC, Oosterhof H. The impact of menopausal symptoms on work ability. Menopause 2012;19:278-282.
23. Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009;16:442-452.
24. Kumari M, Stafford M, Marmot M. The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J Clin Epidemiol 2005;58:719-727.
25. Brown JP, Gallicchio L, Flaws JA, Tracy JK. Relations among menopausal symptoms, sleep disturbance and depressive symptoms in midlife. Maturitas 2009;62:184-189.
26. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
27. Chim H, Tan BH, Ang CC, Chew EM, Chong YS, Saw SM. The prevalence of menopausal symptoms in a community in Singapore. Maturitas 2002;41:275-282.
28. Freeman EW, Sammel MD, Liu L, Martin P. Psychometric properties of a menopausal symptom list. Menopause 2003;10:258-265.
29. Nunnally J, Bernstein I. Psychometric Theory. 3rd ed. New York, NY: McGraw-Hill; 1994.
30. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
31. Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008;14(suppl 3):14-19.
32. Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008;168:840-846.
33. Da Fonseca AM, Bagnoli VR, Souza MA, et al. Impact of age and body mass on the intensity of menopausal symptoms in 5968 Brazilian women. Gynecol Endocrinol 2013;29:116-118.
34. den Tonkelaar I, Seidell JC, van Noord PA. Obesity and fat distribution in relation to hot flashes in Dutch women from the DOM-project. Maturitas 1996;23:301-305.
35. Duffy OK, Iversen L, Hannaford PC. Factors associated with reporting classic menopausal symptoms differ. Climacteric 2013;16:240-251.
36. Schilling C, Gallicchio L, Miller SR, Langenberg P, Zacur H, Flaws JA. Relation of body mass and sex steroid hormone levels to hot flushes in a sample of mid-life women. Climacteric 2007;10:27-37.
37. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health Across the Nation. Obstet Gynecol Clin North Am 2011;38:489-501.
38. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 2007;275:161-168.
39. Campagnoli C, Morra G, Belforte P, Belforte L, Prelato Tousijn L. Climacteric symptoms according to body weight in women of different socio-economic groups. Maturitas 1981;3:279-287.
40. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-272.
41. Australian Bureau of Statistics. Programme for the International Assessment of Adult Competencies, Australia, 2011-12. Canberra, Australia: Australian Bureau of Statistics; 2013.
42. Central Intelligence Agency. The world factbook 2013-14. Available at: https://www.cia.gov/library/publications/the-world-factbook/index.html.
43. Roth LW, Allshouse AA, Lesh J, Polotsky AJ, Santoro N. The correlation between self-reported and measured height, weight, and BMI in reproductive age women. Maturitas 2013;76:185-188.
44. Brunner Huber LR. Validity of self-reported height and weight in women of reproductive age. Matern Child Health J 2007;11:137-144.
45. Craig BM, Adams AK. Accuracy of body mass index categories based on self-reported height and weight among women in the United States. Matern Child Health J 2009;13:489-496.